{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:50:32Z","timestamp":1787986232591,"version":"build-2784847793"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T00:00:00Z","timestamp":1640304000000},"content-version":"am","delay-in-days":326,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.bone.2020.115784","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T20:25:01Z","timestamp":1606854301000},"page":"115784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Bisphosphonates for the treatment of fibrous dysplasia of bone"],"prefix":"10.1016","volume":"143","author":[{"given":"Roland","family":"Chapurlat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie A.","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.bone.2020.115784_bb0005","doi-asserted-by":"crossref","first-page":"P120","DOI":"10.1359\/jbmr.06s223","article-title":"G(s)alpha mutations in fibrous dysplasia and McCune-Albright syndrome","volume":"21","author":"Weinstein","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115784_bb0010","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/(SICI)1096-9896(199901)187:2<249::AID-PATH222>3.0.CO;2-J","article-title":"The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: site-specific patterns and recurrent histological hallmarks","volume":"187","author":"Riminucci","year":"1999","journal-title":"J. Pathol."},{"key":"10.1016\/j.bone.2020.115784_bb0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.berh.2007.11.004","article-title":"Fibrous dysplasia of bone and McCune-Albright syndrome","volume":"22","author":"Chapurlat","year":"2008","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.bone.2020.115784_bb0020","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1002\/jbmr.2894","article-title":"Prognostic factors from an epidemiologic evaluation of fibrous dysplasia of bone in a modern cohort: the FRANCEDYS study","volume":"31","author":"Benhamou","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115784_bb0025","series-title":"GeneReviews\u00ae","article-title":"Fibrous dysplasia\/McCune-Albright syndrome","author":"Boyce","year":"1993"},{"key":"10.1016\/j.bone.2020.115784_bb0030","article-title":"Fibrous dysplasia\/McCune-Albright syndrome: a rare, mosaic disease of G\u03b1s activation","author":"Boyce","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bone.2020.115784_bb0035","doi-asserted-by":"crossref","first-page":"E97","DOI":"10.1210\/jc.2013-1823","article-title":"Hepatobiliary and pancreatic neoplasms in patients with McCune-Albright syndrome","volume":"99","author":"Gaujoux","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115784_bb0040","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1359\/jbmr.2001.16.5.806","article-title":"Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia","volume":"16","author":"Collins","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115784_bb0045","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/1097-0142(19940301)73:5<1411::AID-CNCR2820730516>3.0.CO;2-T","article-title":"Malignancies in fibrous dysplasia","volume":"73","author":"Ruggieri","year":"1994","journal-title":"Cancer."},{"key":"10.1016\/j.bone.2020.115784_bb0050","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1210\/jc.2002-021642","article-title":"Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations","volume":"88","author":"Collins","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115784_bb0055","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/jbmr.3286","article-title":"Increased risk of breast cancer at a young age in women with fibrous dysplasia","volume":"33","author":"Majoor","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115784_bb0060","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2106\/JBJS.18.00062","article-title":"Prevalence and clinical features of Mazabraud syndrome: a multicenter European study","volume":"101","author":"Majoor","year":"2019","journal-title":"J. Bone Joint Surg. Am."},{"key":"10.1016\/j.bone.2020.115784_bb0065","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13023-017-0629-x","article-title":"Determinants of impaired quality of life in patients with fibrous dysplasia","volume":"12","author":"Majoor","year":"2017","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.bone.2020.115784_bb0070","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115784_bb0075","first-page":"200","article-title":"Should bisphosphonates be standard therapy for bone pain?","volume":"5","author":"Paterson","year":"1997","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bone.2020.115784_bb0080","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1002\/art.20591","article-title":"Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity","volume":"50","author":"Manicourt","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bone.2020.115784_bb0085","article-title":"Management of Paget\u2019s disease of bone","author":"Reid","year":"2019","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.bone.2020.115784_bb0090","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0304-3959(98)00135-3","article-title":"The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials","volume":"78","author":"Fulfaro","year":"1998","journal-title":"Pain."},{"key":"10.1016\/j.bone.2020.115784_bb0095","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1254\/jjp.79.433","article-title":"Alendronate induces antinociception in mice, not related with its effects in bone","volume":"79","author":"Goicoechea","year":"1999","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.bone.2020.115784_bb0100","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S8756-3282(03)00229-1","article-title":"Long-term analgesic effect of clodronate in rodents","volume":"33","author":"Bonabello","year":"2003","journal-title":"Bone."},{"key":"10.1016\/j.bone.2020.115784_bb0105","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0140-6736(94)90069-8","article-title":"Long-term effects of intravenous pamidronate in fibrous dysplasia of bone","volume":"343","author":"Liens","year":"1994","journal-title":"Lancet."},{"key":"10.1016\/j.bone.2020.115784_bb0110","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1359\/jbmr.1997.12.10.1746","article-title":"Long-term effects of intravenous pamidronate in fibrous dysplasia of bone","volume":"12","author":"Chapurlat","year":"1997","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115784_bb0115","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bone.2004.03.004","article-title":"Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment","volume":"35","author":"Chapurlat","year":"2004","journal-title":"Bone."},{"key":"10.1016\/j.bone.2020.115784_bb0120","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S8756-3282(03)00221-7","article-title":"Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia","volume":"33","author":"Parisi","year":"2003","journal-title":"Bone."},{"key":"10.1016\/j.bone.2020.115784_bb0125","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1359\/jbmr.1997.12.8.1314","article-title":"Long-term aminobisphosphonate treatment of fibrous dysplasia: spectacular increase in bone density","volume":"12","author":"Weinstein","year":"1997","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115784_bb0130","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00003086-200101000-00003","article-title":"Bisphosphonate therapy in fibrous dysplasia","author":"Lane","year":"2001","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.bone.2020.115784_bb0135","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/jbmr.2999","article-title":"Outcome of long-term bisphosphonate therapy in McCune-Albright syndrome and polyostotic fibrous dysplasia","volume":"32","author":"Majoor","year":"2017","journal-title":"J. Bone Miner. Res."},{"issue":"Suppl. 2","key":"10.1016\/j.bone.2020.115784_bb0140","doi-asserted-by":"crossref","first-page":"P114","DOI":"10.1359\/jbmr.06s222","article-title":"Medical therapy in adults with fibrous dysplasia of bone","volume":"21","author":"Chapurlat","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115784_bb0145","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1210\/jc.2014-1371","article-title":"A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone","volume":"99","author":"Boyce","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115784_bb0150","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1210\/jc.2003-030050","article-title":"Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone","volume":"88","author":"Plotkin","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115784_bb0155","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.joms.2016.04.001","article-title":"Fibrous dysplasia and medication-related osteonecrosis of the jaw","volume":"74","author":"Metwally","year":"2016","journal-title":"J. Oral Maxillofac. Surg."},{"key":"10.1016\/j.bone.2020.115784_bb0160","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0002-9394(14)72902-2","article-title":"Pamidronate disodium and possible ocular adverse drug reactions","volume":"118","author":"Macarol","year":"1994","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.bone.2020.115784_bb0165","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00198-006-0169-z","article-title":"Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study","volume":"17","author":"Armingeat","year":"2006","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115784_bb0170","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0885-3924(97)00075-4","article-title":"A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain","volume":"13","author":"Ernst","year":"1997","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.bone.2020.115784_bb0175","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer."},{"key":"10.1016\/j.bone.2020.115784_bb0180","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/annonc\/mdl041","article-title":"Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer","volume":"17","author":"Weinfurt","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bone.2020.115784_bb0185","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","article-title":"Comparison of a single infusion of zoledronic acid with risedronate for Paget\u2019s disease","volume":"353","author":"Reid","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115784_bb0190","doi-asserted-by":"crossref","DOI":"10.1177\/1744806917697011","article-title":"Mechanisms of nerve growth factor signaling in bone nociceptors and in an animal model of inflammatory bone pain","volume":"13","author":"Nencini","year":"2017","journal-title":"Mol. Pain"},{"key":"10.1016\/j.bone.2020.115784_bb0195","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/jbmr.3649","article-title":"Age-related changes and effects of bisphosphonates on bone turnover and disease progression in fibrous dysplasia of bone","volume":"34","author":"Florenzano","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115784_bb0200","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13023-019-1102-9","article-title":"Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: a consensus statement from the FD\/MAS international consortium","volume":"14","author":"Javaid","year":"2019","journal-title":"Orphanet J Rare Dis."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632822030572X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632822030572X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:58:00Z","timestamp":1757613480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S875632822030572X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":40,"alternative-id":["S875632822030572X"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115784","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bisphosphonates for the treatment of fibrous dysplasia of bone","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115784","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115784"}}